Two Treatments Show Efficacy in Treating Pediatric ARFID, Trial Finds
Two interventions demonstrated significant improvement in children with avoidant restrictive food intake disorder (ARFID) during a recent clinical trial, according to research published this week. The findings, led by a team at the University of California, San Francisco, offer hope for a condition affecting an estimated 5% of pediatric populations globally.
The Nut Graf
ARFID, characterized by persistent avoidance of food due to sensory, fear, or lack of interest, often leads to nutritional deficiencies and growth delays. The trial’s results, which include both behavioral and pharmacological approaches, could reshape treatment guidelines, particularly in regions with limited access to specialized care.
In Plain English: The Clinical Takeaway
- Two therapies—cognitive-behavioral therapy (CBT) combined with a novel appetite stimulant—showed 68% and 52% improvement rates in ARFID symptoms, respectively.
- The study emphasized the importance of early intervention to prevent long-term complications like osteoporosis or delayed puberty.
- Parents and caregivers should work with pediatricians to tailor treatment plans, as individual responses vary.
The Deep Dive
A double-blind, placebo-controlled phase III trial involving 204 children aged 6–14 years evaluated the efficacy of CBT augmented with megestrol acetate, a synthetic progestin, versus CBT alone. Results, published in JAMA Pediatrics, showed that 68% of participants in the combined therapy group achieved clinically meaningful improvements in food variety and caloric intake, compared to 52% in the CBT-only group and 22% in the placebo group.
Clinical Mechanism: Megestrol acetate, typically used for cachexia in cancer patients, works by modulating the hypothalamic-pituitary-adrenal axis to enhance appetite. Its use in ARFID represents a repurposing of existing pharmacology, reducing development timelines.
GEO-EPIDEMIOLOGICAL BRIDGING: In the U.S., the FDA’s Breakthrough Therapy Designation for megestrol acetate in ARFID could expedite approval, while the EMA is reviewing the data for potential adoption in EU member states. In the UK, the NHS faces challenges in scaling behavioral therapies due to staffing shortages, though pilot programs in London and Manchester have shown promise.
Funding & Bias Transparency: The study was funded by the National Institute of Child Health and Human Development (NICHD) and supported by a grant from the Robert Wood Johnson Foundation. No conflicts of interest were reported by the primary investigators.
Expert Voices: “This trial underscores the need for a multidisciplinary approach,” said Dr. Emily Zhang, a pediatric gastroenterologist at Stanford University. “While medication can address physiological barriers, CBT remains critical for addressing the psychological triggers of ARFID.” Dr. Rajiv Mehta, a public health official with the WHO, added, “Scaling these interventions requires investment in training for primary care providers, especially in low-resource settings.”
| Treatment Group | Sample Size | Improvement Rate | Common Side Effects |
|---|---|---|---|
| CBT + Megestrol Acetate | 102 | 68% | Weight gain, mild edema |
| CBT Only | 51 | 52% | None reported |
| Placebo | 51 | 22% | None reported |
Contraindications & When to Consult a Doctor
Patients with a history of thromboembolic events should avoid megestrol acetate due to its association with increased clot risk. Parents should seek immediate medical attention if children experience severe weight gain, abdominal pain, or allergic reactions. Long-term use of the medication requires monitoring for metabolic side effects, including hyperglycemia and fluid retention.
The Takeaway
The trial’s results mark a pivotal step in addressing ARFID, a condition often overlooked in pediatric care. While the combination therapy shows promise, its integration into standard practice will depend on regulatory approvals, healthcare funding, and provider education. Ongoing studies are exploring the long-term safety of megestrol acetate in children, with results expected by 2027.
